Drug Registration and Acceptance

Drug Name

Exact

Active Ingredient

Acceptance No.

Manufacturers

Acceptance Date

Status Date

Classification

Review Status

Drug Type

Submission

Evaluation Conclusion

ATC Category

Special Approval Varieties

Task Type

Major Special Varieties

Sequence No.

Stock Code

Visualized Analysis Export Evaluation Conclusion Evaluation Progress

Acceptance No.	Drug Name	Active Ingredient	Dosage Form	Classification	Submission	Acceptance Date	Manufacturers	Manufacturers	Review Status	Status Date	View
JTS2300051	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Disposable Import Drug Application	2023-10-14					view
JTS2400017	favezelimab帕博利珠单抗注射液	favezelimab;pembrolizumab	Injection	Biological Products	Disposable Import Drug Application	2024-03-12					view
JXSB2000003	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2020-07-30			In Review	2020-07-29	view
JXSB2000023	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2020-09-30	Merck Sharp & Dohme Corp.	Merck Sharp & Dohme Corp	In Review	2020-09-28	view
JXSB2000024	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products(2.2)	Supplementary Application	2020-09-30	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2020-10-09	view
JXSB2000025	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products(2.2)	Supplementary Application	2020-09-30	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2020-09-29	view
JXSB2000034	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products(2.2)	Supplementary Application	2020-10-21	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2020-10-20	view
JXSB2000037	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2020-11-23	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2020-11-21	view
JXSB2000040	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2020-12-03	Merck Sharp & Dohme Corp.	Merck Sharp & Dohme Corp	In Review	2020-12-02	view
JXSB2000056	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2021-01-01	Merck Sharp & Dohme Corp.	Merck Sharp & Dohme Corp	In Review	2021-05-09	view
JXSB2000057	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products(2.2)	Supplementary Application	2021-01-01	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2022-01-20	view
JXSB2100003	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2021-01-06	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2022-01-20	view
JXSB2100007	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products(3.1)	Supplementary Application	2021-01-08	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2022-01-19	view
JXSB2100013	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products(2.2)	Supplementary Application	2021-02-20	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2021-02-19	view
JXSB2100017	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products(2.2)	Supplementary Application	2021-03-02	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2021-03-01	view
JXSB2100022	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2021-03-16			In Review	2021-03-15	view
JXSB2100028	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products(2.2)	Supplementary Application	2021-03-24	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2021-03-23	view
JXSB2100029	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2021-04-01			In Review	2021-03-31	view
JXSB2101004	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2021-04-14					view
JXSB2101006	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2021-04-30					view